Amer Sports
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Amer Sports, Inc. is a global enterprise dedicated to the creation, production, promotion, and sale of athletic equipment, clothing, footwear, and related accessories. The company's extensive reach co...
Latest News
4 days ago · zacks.com
Best Health & Fitness Stocks to Buy on Strong Market PotentialRising demand for wearables, performance footwear and outdoor apparel puts VFC, GRMN and AS in focus as the health & fitness market expands.
4 days ago · zacks.com
Ahead of Amer Sports, Inc. (AS) Q3 Earnings: Get Ready With Wall Street Estimates for Key MetricsLooking beyond Wall Street's top-and-bottom-line estimate forecasts for Amer Sports, Inc. (AS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
6 days ago · zacks.com
ASO or AS: Which Is the Better Value Stock Right Now?Investors looking for stocks in the Leisure and Recreation Products sector might want to consider either Academy Sports and Outdoors, Inc. (ASO) or Amer Sports, Inc. (AS). But which of these two companies is the best option for those looking for undervalued stocks?
14 days ago · gurufocus.com
GE HealthCare reinforces leadership in AI with Lung Guidance and AutoAS on Vscan Air for point of care ultrasound assessmentsGE HealthCare (Nasdaq: GEHC) today announced two new AI-assisted capabilities for its Vscan Air⢠handheld ultrasound system: Lung Guidance and AutoAS.1 Design
27 days ago · zacks.com
ASO vs. AS: Which Stock Is the Better Value Option?Investors interested in stocks from the Leisure and Recreation Products sector have probably already heard of Academy Sports and Outdoors, Inc. (ASO) and Amer Sports, Inc. (AS). But which of these two companies is the best option for those looking for undervalued stocks?
1 month ago · gurufocus.com
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
1 month ago · fool.com
Amer Sports Chief Strategy Officer Exercises Options to Acquire More than $7 Million Shares. Is This a Signal to Buy AS?The disposition involved ~117,000 shares for a total value of $3.1 million. Traded shares represented 78% of the equity stake held directly before the filing.
1 month ago · gurufocus.com
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseaseNew SKYRIZIÂ (risankizumab-rzaa) and RINVOQÂ (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePR NewswireNOR
2 months ago · gurufocus.com
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressAbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR Newsw
2 months ago · gurufocus.com
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisAbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR
Analyst Summary
Add to Watchlist
Select watchlists to add or remove AS